• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session

    1/8/24 1:36:30 PM ET
    $AMAM
    $AMPE
    $ARBK
    $ARDX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMAM alert in real time by email

    Shares of RxSight, Inc. (NASDAQ:RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates.

    Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.

    RxSight shares jumped 20% to $44.31 on Monday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • Harpoon Therapeutics, Inc. (NASDAQ:HARP) shares jumped 111.2% to $22.28 after Merck announced it will acquire the company for $23 per share in cash.
    • Ambrx Biopharma Inc. (NASDAQ:AMAM) jumped 98.1% to $27.00 after Johnson & Johnson announced it will acquire the company in an all-cash merger for a total equity value of approximately $2 billion.
    • Spectaire Holdings Inc. (NASDAQ:SPEC) jumped 75.2% to $2.96.
    • Nkarta, Inc. (NASDAQ:NKTX) rose 51% to $9.17 as the company announced updated corporate presentation to reflect business and strategic update.
    • Universe Pharmaceuticals INC (NASDAQ:UPC) gained 42% to $2.22.
    • Elevation Oncology, Inc. (NASDAQ:ELEV) jumped 39.2% to $1.2193.
    • NexImmune, Inc. (NASDAQ:NEXI) rose 34.7% to $8.32.
    • Praxis Precision Medicines, Inc. (NASDAQ:PRAX) rose 34% to $33.76 as the company issued update on advancing clinical stage portfolio.
    • QuantaSing Group Limited (NASDAQ:QSG) gained 31% to $2.0563.
    • Butterfly Network, Inc. (NASDAQ:BFLY) rose 29.7% to $1.31 as the company announced FDA clearance of handheld ultrasound system, Butterfly iQ3.
    • Venus Concept Inc. (NASDAQ:VERO) climbed 28% to $1.51.
    • Ardelyx, Inc. (NASDAQ:ARDX) gained 25.5% to $7.73 after the company provided an update on its progress in 2023 and initial expectations for 2024.
    • BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) rose 20.8% to $7.36 after the company issued preliminary Q4 revenue guidance above estimates. Also the company said it is approaching positive EPS and cash flow in 2H 2025.
    • Axonics, Inc. (NASDAQ:AXNX) jumped 19.9% to $69.03 after the company announced a deal to be acquired by Boston Scientific.
    • Crocs, Inc. (NASDAQ:CROX) jumped 18.8% to $102.69 after the company issued strong Q4 and full year 2023 guidance.
    • LendingTree, Inc. (NASDAQ:TREE) rose 17.3% to $33.50.
    • Wolverine World Wide, Inc. (NYSE:WWW) jumped 16.7% to $9.02. Wolverine Worldwide affirmed preliminary 2023 financial results in line with guidance.
    • Ampio Pharmaceuticals, Inc. (NYSE:AMPE) gained 16.4% to $2.0799 after falling around 8% on Friday.
    • Shattuck Labs, Inc. (NASDAQ:STTK) gained 15.2% to $9.52.
    • Vincerx Pharma, Inc. (NASDAQ:VINC) shares rose 14.3% to $1.36 after the company announced compelling clinical efficacy of enitociclib in combination with venetoclax and prednisone in lymphoma.
    • Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) shares gained 14.1% to $2.84 after jumping over 10% on Friday.
    • Silk Road Medical, Inc (NASDAQ:SILK) rose 13.4% to $12.91.
    • OPKO Health, Inc. (NASDAQ:OPK) jumped 12.5% to $1.00.
    • Avadel Pharmaceuticals plc (NASDAQ:AVDL) gained 12% to $16.68 after the company issued a business update.
    • Fastly, Inc. (NYSE:FSLY) jumped 10.5% to $17.88 after RBC Capital upgraded the stock from Underperform to Sector Perform and raised its price target from $12 to $18.
    • Upwork Inc. (NASDAQ:UPWK) gained 10.3% to $15.51 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $13 to $20.
    • Commercial Metals Company (NYSE:CMC) rose 6.2% to $51.21 following strong quarterly results.

    Losers

    • LumiraDx Limited (NASDAQ:LMDX) shares fell 45.5% to $0.0187. LumiraDx announced its securities will be suspended from trading on Nasdaq at the open of business on Jan. 9th.
    • Top KingWin Ltd (NASDAQ:TCJH) dipped 38.8% to $1.18.
    • Solo Brands, Inc. (NYSE:DTC) dipped 38.7% to $3.6150 after the company lowered full year 2023 revenue guidance below estimates.
    • Dada Nexus Limited (NASDAQ:DADA) shares dipped 38.1% to $1.95. Dada Nexus said in the course of its routine internal audit, certain suspicious practices were identified that may cast doubt on certain revenues from the company's online advertising and marketing services in 2023.
    • Prothena Corporation plc (NASDAQ:PRTA) fell 25.1% to $30.45 after the company issued updates on PRX012, PRX123, Birtamimab and Portfolio programs.
    • Jin Medical International Ltd. (NASDAQ:ZJYL) fell 23.4% to $95.00.
    • MMTec, Inc. (NASDAQ:MTC) fell 22.4% to $1.82.
    • Evolve Transition Infrastructure LP (NASDAQ:SNMP) tumbled 20.8% to $1.33.
    • Revance Therapeutics, Inc. (NASDAQ:RVNC) fell 20.1% to $6.68 after the company issued preliminary Q4 and FY23 financial results and guidance.
    • Banzai International, Inc. (NASDAQ:BNZI) shares fell 19.3% to $2.07. Banzai shares jumped around 55% on Friday after the company signed an LOI to acquire IGLeads.
    • Northern Dynasty Minerals Ltd. (NYSE:NAK) dipped 18.8% to $0.3107.
    • The Arena Group Holdings, Inc. (NYSE:AREN) shares fell 18.2% to $1.7603 after dipping 17% on Friday.
    • The Arena Group Holdings, Inc. (NASDAQ:AREN) dipped 18% to $ 1.7650.
    • Inspire Veterinary Partners, Inc. (NASDAQ:IVP) declined 16.8% to $0.1881. Inspire Veterinary Partners recently filed a prospectus related to up to a $5 million public offering
    • Pacific Biosciences of California, Inc. (NASDAQ:PACB) fell 15.1% to $7.99. Pacific Biosciences of California said it sees preliminary FY23 revenue of $200.5 million.
    • REGENXBIO Inc. (NASDAQ:RGNX) fell 14.8% to $14.01. US District Court issued decision on REGENXBIO and University of Pennsylvania NAV technology patent infringement lawsuit.
    • Revance Therapeutics, Inc. (NASDAQ:RVNC) fell 13.6% to $7.21. Revance issued corporate update, preliminary Q4 and FY23 financial results, and financial outlook.
    • BioSig Technologies, Inc. (NASDAQ:BSGM) fell 13.6% to $0.35. On Jan. 5, BioSig Technologies received a letter from Nasdaq notifying company has regained compliance with Nasdaq Listing Rule 5550(b)(2).
    • Bright Health Group, Inc. (NYSE:BHG) dipped 12.8% to $10.00.
    • Safe and Green Development Corporation (NASDAQ:SGD) shares fell 11.3% to $1.80 after jumping 49% on Friday.
    • Argo Blockchain plc (NASDAQ:ARBK) fell 11.1% to $3.11 after announcing £7.8 million ($9.9 million) placing.
    • Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) dipped 10.7% to $0.5146. Shuttle Pharmaceuticals received FDA approval to proceed with Phase II clinical trial of ropidoxuridine for the treatment of patients with glioblastoma.
    • Paragon 28, Inc. (NYSE:FNA) fell 9.6% to $11.83. Paragon 28 said it sees preliminary fourth-quarter revenue of $60.3 million to $60.6 million.
    • Sharps Technology, Inc. (NASDAQ:STSS) fell 8.3% to $0.4032 after jumping 12% on Friday.
    • Dynavax Technologies Corporation (NASDAQ:DVAX) dipped 7.5% to $13.63. Dynavax sees preliminary 2023 HEPLISAV-B vaccine net product revenue of $213 million.
    • The Boeing Company (NYSE:BA) fell 7% to $231.69 after an exit door blew out of a 737 aircraft during a commercial flight.
    • Spirit AeroSystems Holdings, Inc. (NYSE:SPR) fell 6.5% to $29.67 after an exit door blew out of a 737 aircraft during a commercial flight. Spirit Aerosystems was a vendor involved with the faulty door.

     

    Now Read This: Cramer Says This Major Healthcare Stock Is 'Ridiculously Cheap And Doing So Many Great Things'

    Get the next $AMAM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMAM
    $AMPE
    $ARBK
    $ARDX

    CompanyDatePrice TargetRatingAnalyst
    Crocs Inc.
    $CROX
    3/10/2026Neutral
    BTIG Research
    Shattuck Labs Inc.
    $STTK
    3/6/2026$25.00Buy
    Needham
    Pacific Biosciences of California Inc.
    $PACB
    3/6/2026$1.50Equal Weight → Underweight
    Barclays
    Wolverine World Wide Inc.
    $WWW
    2/27/2026$18.00 → $22.00Market Perform
    Telsey Advisory Group
    Praxis Precision Medicines Inc.
    $PRAX
    2/24/2026$500.00Outperform
    Wolfe Research
    BioCryst Pharmaceuticals Inc.
    $BCRX
    2/18/2026$17.00Outperform
    Evercore ISI
    Crocs Inc.
    $CROX
    2/13/2026$100.00 → $130.00Buy
    Monness Crespi & Hardt
    Fastly Inc.
    $FSLY
    2/12/2026Mkt Perform → Outperform
    William Blair
    More analyst ratings

    $AMAM
    $AMPE
    $ARBK
    $ARDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Raab Michael

    4 - ARDELYX, INC. (0001437402) (Issuer)

    3/18/26 4:42:26 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Barnes Alane P

    4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

    3/18/26 4:11:09 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by Universe Pharmaceuticals Inc.

    3 - Universe Pharmaceuticals INC (0001809616) (Issuer)

    3/18/26 8:27:11 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMAM
    $AMPE
    $ARBK
    $ARDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Crocs

    BTIG Research initiated coverage of Crocs with a rating of Neutral

    3/10/26 8:40:26 AM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    Needham resumed coverage on Shattuck Labs with a new price target

    Needham resumed coverage of Shattuck Labs with a rating of Buy and set a new price target of $25.00

    3/6/26 8:36:02 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacific Biosciences downgraded by Barclays with a new price target

    Barclays downgraded Pacific Biosciences from Equal Weight to Underweight and set a new price target of $1.50

    3/6/26 8:26:02 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AMAM
    $AMPE
    $ARBK
    $ARDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Basecamp Research Selects PacBio HiFi Sequencing to Power Trillion Gene Atlas Initiative

    MENLO PARK, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing technologies, today announced that Basecamp Research, a frontier AI lab for therapeutic design, has selected PacBio HiFi sequencing on the Revio® system to generate large-scale environmental and host-associated metagenomic data for the Trillion Gene Atlas—a landmark scientific initiative designed to generate and model biological data at the trillion-gene scale. The collaboration is expected to result in approximately 100,000 deeply sequenced samples from over 31 countries across 5 continents, creating the largest and most diverse high-fidelity metagenomic da

    3/18/26 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    The Arena Group Reports Q4 and Full Year 2025 Results, Marking First Full Year of Positive Net Income and Major Debt Reduction

    Revenue Diversification, Commerce Expansion and Disciplined Operations Continue to Fuel Growth and Scale in Face of Industry Volatility The Arena Group Holdings, Inc. (NYSE:AREN) ("The Arena Group" or "Arena"), a brand, data, and IP company home to many of the nation's most recognizable brands, including Parade, TheStreet, Men's Journal, Athlon Sports, ShopHQ and the Adventure Network (including Surfer, Powder, Bike Magazine and more), today announced financial results for the three months ending December 31, 2025 ("Q4 2025") and the year ended December 31, 2025 ("FY 2025"). Financial Highlights for Q4 2025: Fourth quarter revenue was $28.2 million, compared to $36.2 million in Q4 20

    3/16/26 4:05:00 PM ET
    $AREN
    EDP Services
    Technology

    E.F. Hutton & Co. Serves as Exclusive Placement Agent on Shuttle Pharmaceuticals' $3.5 Million Public Offering

    NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. ("E.F. Hutton"), a leading investment banking and financial advisory firm, today announced that it acted as the exclusive placement agent in connection with a $3.5 million public offering by Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharmaceuticals" or the "Company"), the owner of Molecule.ai, an artificial intelligence ("AI") driven platform for molecular discovery and early-stage drug development. Shuttle Pharmaceuticals entered into a securities purchase agreement with investors for the issuance and sale of 2,238,800 shares of common stock and pre-funded warrants to purchase 4,761,200 shares of common s

    3/12/26 8:30:00 AM ET
    $SHPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMAM
    $AMPE
    $ARBK
    $ARDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    10/20/23 4:37:52 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:43:04 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZA™ issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:37:08 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMAM
    $AMPE
    $ARBK
    $ARDX
    SEC Filings

    View All

    Upwork Inc. filed SEC Form 8-K: Leadership Update

    8-K - UPWORK, INC (0001627475) (Filer)

    3/18/26 4:05:27 PM ET
    $UPWK
    EDP Services
    Technology

    SEC Form 6-K filed by JIN MEDICAL INTERNATIONAL LTD.

    6-K - Jin Medical International Ltd. (0001837821) (Filer)

    3/17/26 4:30:16 PM ET
    $ZJYL
    Industrial Specialties
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Butterfly Network Inc.

    SCHEDULE 13D/A - Butterfly Network, Inc. (0001804176) (Subject)

    3/17/26 4:20:28 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $AMAM
    $AMPE
    $ARBK
    $ARDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Buckley Mortimer J bought $499,966 worth of shares (2,230 units at $224.20), increasing direct ownership by 101% to 4,430 units (SEC Form 4)

    4 - BOEING CO (0000012927) (Issuer)

    3/5/26 4:59:07 PM ET
    $BA
    Aerospace
    Industrials

    Director Mott David M bought $1,946,331 worth of shares (333,333 units at $5.84), increasing direct ownership by 11% to 3,302,918 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    2/23/26 9:01:11 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Arriola Dennis V bought $149,380 worth of shares (2,000 units at $74.69), increasing direct ownership by 28% to 9,238 units (SEC Form 4)

    4 - COMMERCIAL METALS Co (0000022444) (Issuer)

    1/22/26 10:15:04 AM ET
    $CMC
    Steel/Iron Ore
    Industrials

    $AMAM
    $AMPE
    $ARBK
    $ARDX
    Financials

    Live finance-specific insights

    View All

    The Arena Group Reports Q4 and Full Year 2025 Results, Marking First Full Year of Positive Net Income and Major Debt Reduction

    Revenue Diversification, Commerce Expansion and Disciplined Operations Continue to Fuel Growth and Scale in Face of Industry Volatility The Arena Group Holdings, Inc. (NYSE:AREN) ("The Arena Group" or "Arena"), a brand, data, and IP company home to many of the nation's most recognizable brands, including Parade, TheStreet, Men's Journal, Athlon Sports, ShopHQ and the Adventure Network (including Surfer, Powder, Bike Magazine and more), today announced financial results for the three months ending December 31, 2025 ("Q4 2025") and the year ended December 31, 2025 ("FY 2025"). Financial Highlights for Q4 2025: Fourth quarter revenue was $28.2 million, compared to $36.2 million in Q4 20

    3/16/26 4:05:00 PM ET
    $AREN
    EDP Services
    Technology

    Men's Journal Spirits Shop Partners with NBA All-Star Stephen Curry, Offering Gentleman's Cut Bourbon and Exclusive Signed Merchandise Sweepstakes

    Men's Journal Spirits Shop is thrilled to announce a new partnership with NBA icon Stephen Curry and his premium bourbon brand, Gentleman's Cut. His whiskey is now available for purchase on the Men's Journal Spirits Shop website, giving readers access to Curry's signature portfolio of spirits. To celebrate the partnership, Men's Journal also launched a sweepstakes where readers can enter to win Curry autographed basketballs or jerseys. "This is a project that we've been personally involved with from the start, focused on quality, craftsmanship, and doing things the right way," Curry shared in a promotional video posted on Men's Journal and Gentleman's Cut Bourbon social media accounts.

    3/10/26 2:02:00 PM ET
    $AREN
    EDP Services
    Technology

    REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data at MDA, topline pivotal results expected early Q2 2026Robust patient enrollment continues in confirmatory trialSurabgene lomparvovec (sura-vec, ABBV-RGX-314) subretinal wet AMD topline pivotal data expected in Q4 2026; first patient dosed in pivotal Phase IIb/III trial in diabetic retinopathy expected in Q2 2026Company to engage FDA on potential path forward for RGX-121Conference call today at 8:00 a.m. ETROCKVILLE, Md., March 5, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today reported financial results and operational highlights f

    3/5/26 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMAM
    $AMPE
    $ARBK
    $ARDX
    Leadership Updates

    Live Leadership Updates

    View All

    Butterfly Network Appoints David Horsley as Senior Vice President, Innovation – Butterfly Embedded™

    Chirp Microsystems Co-Founder Joins Butterfly to Advance its Ultrasound-on-Chip™ Platform Strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of David Horsley, Ph.D. as Senior Vice President of Innovation – Butterfly Embedded™ to scale its Ultrasound-on-Chip™ co-development and licensing initiative. In this role, Dr. Horsley will lead strategy and go-to-market for Butterfly Embedded, overseeing new product development, partnerships, and commercialization efforts. Butterfly Embedded is focused on extending the reach of the company's proprietary semic

    3/10/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    PacBio Announces the Appointment of Chris Gibson to the Board of Directors

    MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio's Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company that has built one of the industry's most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional b

    3/5/26 8:30:00 AM ET
    $PACB
    $RXRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

    NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:  S&P MidCap 400 constituent Ciena Corp. (NYSE:CIEN) will replace Dayforce Inc. (NYSE:DAY) in the S&P 500, S&P SmallCap 600 constituent Arrowhead Pharmaceuticals Inc. (NASD: ARWR) will replace Ciena in the S&P MidCap 400, and ADT Inc. (NYSE:ADT) will replace Arrowhead Pharmaceuticals in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 9. Thoma Bravo L.P. acquired Dayforce in a deal that closed today.OneSpaWorld Holdings Ltd. (NASD: OSW) will replace Dynavax Technologies Corp. (NASD: DVAX) in the S&P SmallCap 600 effec

    2/4/26 6:15:00 PM ET
    $ADT
    $ARWR
    $CIEN
    Diversified Commercial Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMAM
    $AMPE
    $ARBK
    $ARDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nkarta Inc.

    SC 13G - Nkarta, Inc. (0001787400) (Subject)

    12/13/24 5:02:47 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Upwork Inc.

    SC 13G/A - UPWORK, INC (0001627475) (Subject)

    12/9/24 6:02:26 AM ET
    $UPWK
    EDP Services
    Technology

    Amendment: SEC Form SC 13D/A filed by Shattuck Labs Inc.

    SC 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)

    12/6/24 9:03:38 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care